| Prev Close | 4.32 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 1.97 / 5.78 |
| Avg Volume | 239.50K |
| Exchange | NASDAQ |
| Shares Outstanding | 45.07M |
| Market Cap | 193.80M |
| EPS | -0.90 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Peregrine Pharmaceuticals Announces Reverse Stock Split
Common Stock to Trade on Split-Adjusted Basis Beginning at Opening of Market on July 10, 2017; Intended to Enable Continued Listing on the NASDAQ Capital Market
Peregrine Pharmaceuticals' Series E Preferred Stock Yield Pushes Past 12%
In trading on Thursday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 12% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $21.62 on the day. This compares to an average yield of 10.04% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.
Peregrine Pharmaceuticals' Series E Preferred Stock Yield Pushes Past 13%
In trading on Wednesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 13% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $20.16 on the day. This compares to an average yield of 11.31% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
TheStreet's biotech columnist offers his own report card on biotech stocks.
Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 11.5% Yield Mark
In trading on Tuesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 11.5% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $22.80 on the day. This compares to an average yield of 9.98% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.
Peregrine Pharmaceuticals Provides Update On Oral Presentation Of Top-Line Data From Phase III SUNRISE Trial Of Bavituximab At European Society For Medical Oncology (ESMO) 2016 Congress
Ongoing Biomarker Analysis Has Identified a Biomarker that is Associated with a Statistically Significant Improvement in Overall Survival for Patients Receiving the Bavituximab Combination
